A 340b pharmacy program allows covered hospitals, qualified entities, and healthcare systems to purchase outpatient drugs at discounted prices. Drug wholesalers and manufacturers that participate in Medicaid provide these medications through specialty pharmacies to eligible patients of covered entities and qualified healthcare systems at reduced 340b prices.
The program has been under heavy scrutiny lately, with many manufacturers protesting and dropping out of the program. Many states have begun taking positions on the matter, enacting legislation and setting rules that have impacted local hospitals. As we’ve seen in 2024 so far, discussions surrounding the 340b drug pricing program remain integral to broader market conversations. Issues around distribution, patient eligibility, and the use of 340b drugs in ambulatory infusion models persist. As new models emerge, there’s a growing emphasis on patient data and effective patient engagement strategies to retain patients across the prescription continuum. Read More >
